1-10 of 10
Roxanne C. Jewell
Close
Sort by
Journal Articles

Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14

Malin Hultcrantz, David Kleinman, Pavandeep Ghataorhe, Astrid McKeown, Wei He, Thomas Ling, Roxanne C Jewell, Joseph Brunner, Julie Byrne, Laurie Eliason, Emma Scott, Joanna Opalinska
Journal: Blood
Blood (2021) 138 (Supplement 1): 1645.
https://doi.org/10.1182/blood-2021-152224
Published: 2021
Journal Articles

Exposure-Response (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

Geraldine Ferron-Brady, PhD, Chetan Rathi, PhD, Jon Collins, PhD, Herbert Struemper, PhD, Joanna Opalinska, MD, Roxanne C Jewell, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–21.
https://doi.org/10.1182/blood-2020-139698
Published: 2020
Journal Articles

Dreamm-3: A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) Monotherapy Compared with Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)

Katja Weisel, Thomas G Hopkins, Doug Fecteau, Weichao Bao, Corinne Quigley, Roxanne C Jewell, Maureen Nichols, Joanna Opalinska
Journal: Blood
Blood (2019) 134 (Supplement_1): 1900.
https://doi.org/10.1182/blood-2019-129893
Published: 2019
Journal Articles

Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159

Suzanne Trudel, MD FRCP(C), Nikoletta Lendvai, MD PhD, Rakesh Popat, MD PhD, Peter M. Voorhees, MD, Brandi Reeves, MD, Edward N. Libby, III, MD, Paul G Richardson, MD, Larry Anderson, MD PhD, Heather Sutherland, MD, Kwee Yong, PhD, Axel Hoos, MD PhD, Michele Gorczyca, MS, Soumi Lahiri, PhD, Zangdong He, PhD, Roxanne C Jewell, PhD, Joanna B. Opalinska, MD PhD, Adam D. Cohen, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 741.
https://doi.org/10.1182/blood.V130.Suppl_1.741.741
Published: 2017
Journal Articles

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma

Clinical Trials & Observations
Matthew J. Matasar, Myron S. Czuczman, Maria Alma Rodriguez, Michael Fennessy, Thomas C. Shea, Gary Spitzer, Izidore S. Lossos, Mohamed A. Kharfan-Dabaja, Robin Joyce, Luis Fayad, Kristen Henkel, Qiming Liao, Klaus Edvardsen, Roxanne C. Jewell, Doug Fecteau, Rajendra P. Singh, Steen Lisby, Craig H. Moskowitz
Journal: Blood
Blood (2013) 122 (4): 499–506.
https://doi.org/10.1182/blood-2012-12-472027
Published: 2013
Journal Articles

Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results

Myron S. Czuczman, MD, Georg Hess, Ole Gadeberg, Lars Moeller Pedersen, Per Hansen, David Belada, M.D., Ph.D., Stephanie A. Gregory, MD, Brad Pohlman, MD, Jiri Mayer, M.D., PhD., Prof., Robert Pytlik, Lorenz Trumper, Andreas Viardot, MD, Ira V. Gupta, MD, Thomas S. Lin, MD, PhD, Paul Winter, Nancy Goldstein, Roxanne C. Jewell, PhD, Steen Lisby, MD, DMSc
Journal: Blood
Blood (2012) 120 (21): 1632.
https://doi.org/10.1182/blood.V120.21.1632.1632
Published: 2012
Journal Articles

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study

Clinical Trials & Observations
Myron S. Czuczman, Luis Fayad, Vincent Delwail, Guillaume Cartron, Eric Jacobsen, Kazimierz Kuliczkowski, Brian K. Link, Lauren Pinter-Brown, John Radford, Andrzej Hellmann, Eve Gallop-Evans, Christine G. DiRienzo, Nancy Goldstein, Ira Gupta, Roxanne C. Jewell, Thomas S. Lin, Steen Lisby, Martin Schultz, Charlotte A. Russell, Anton Hagenbeek
Journal: Blood
Blood (2012) 119 (16): 3698–3704.
https://doi.org/10.1182/blood-2011-09-378323
Published: 2012
Includes: Supplemental data
Journal Articles

Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy

William G. Wierda, MD, PhD, Roxanne C. Jewell, PhD, Thomas J. Kipps, M.D., Ph.D, Jan Dürig, MD, Laimonas Griskevicius, Stephan Stilgenbauer, MD, Lukas Smolej, M.D., Ph.D., Georg Hess, Francisco J. Hernandez-Ilizaliturri, MD, Swaminathan Padmanabhan, MBBS, MD, Lei Fang, Michele M. Gorczyca, MS, Geoffrey W. Chan, MD, Ira V. Gupta, MD, Steen Lisby
Journal: Blood
Blood (2011) 118 (21): 1793.
https://doi.org/10.1182/blood.V118.21.1793.1793
Published: 2011
Journal Articles

Comparison of Dosimetry and Gamma Camera Methods for Evaluation of Biodistribution Prior to Administration of the Therapeutic Dose of Tositumomab and Iodine I 131 Tositumomab (Bexxar Therapeutic Regimen)

Thierry J. Horner, PhD, Jeffry A. Siegel, MS, MS, PhD, Roxanne C. Jewell, PhD, Gary J. Lunger, MSRIS, RT(R)(N)ARRT, Nancy L. Young, BS, NMT, Brian R. Wynne, MD, Vanessa C. Williams, MS, Thomas S. Lin, MD, PhD, Mark S. Kaminski, MD, Richard L. Wahl, MD, Christina Vleisides, DC
Journal: Blood
Blood (2010) 116 (21): 4916.
https://doi.org/10.1182/blood.V116.21.4916.4916
Published: 2010
Journal Articles

Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.

Anders Österborg, Birgitte Biilmann Ronn, Roxanne C Jewell, Thomas J Kipps, Jiri Mayer, Stephan Stilgenbauer, Cathy D Williams, Andrzej Hellmann, Tadeusz Robak, Richard R Furman, Peter Hillmen, Marek Trneny, Martin JS Dyer, Swami Padmanabhan, Magdalena Piotrowska, Tomas Kozak, Geoffrey Chan, Michael Arning, Nedjad Losic, Randy Davis, Joris Wilms, Charlotte A Russell, William G Wierda
Journal: Blood
Blood (2009) 114 (22): 3433.
https://doi.org/10.1182/blood.V114.22.3433.3433
Published: 2009